16 September 2026 editorial review · Trial
POLARIS: GNTI-122 engineered Tregs in recent-onset T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Corrected120→180-day diagnosis window and added essential genotype/C-peptide restrictions from current registry.
Registry: NCT06919354. Registered endpoint checked: Safety and tolerability of GNTI-122 with and without rapamycin in adult participants with recently diagnosed T1D (Week 78). Eligibility check: Registry age 18 Years to 55 Years; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Limits: No usable primary abstract was independently recovered in this pass for this record. Protocol/design wording was assessed; any existing detailed sponsor, conference or historical outcome claims require their cited source and were not independently certified through full-text review.